Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 10/20 | 0.63 |
| ▸ | CRBN | Q96SW2 | 10/20 | 0.63 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.63 |
| ▸ | TNF | P01375 | 1/20 | 0.63 |
| ▸ | IL1B | P01584 | 1/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 3/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16768175 | 1.00 | DDB1 (0.63) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL15745529 | 0.89 | CRBN (0.80) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL16768176 | 0.89 | DDB1 (0.50) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL282492 | 0.88 | CRBN (0.79) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL283314 | 0.88 | CRBN (0.79) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL30001891 | 0.88 | CRBN (0.79) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL283184 | 0.88 | CRBN (0.79) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL19525976 | 0.88 | DDB1 (0.60) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL13405473 | 0.87 | DDB1 (0.48) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL19526070 | 0.87 | DDB1 (0.59) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10034872-B2 | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies | CELGENE CORPORATION (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170369471-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2017-12-28 | — | — | US | disclosed |
| US-20170362660-A1 | CEREBLON ISOFORMS AND THEIR USE AS BIOMARKERS FOR THERAPEUTIC TREATMENT | CELGENE CORP (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170242014-A1 | METHODS FOR TREATING SOLID TUMORS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO IMMUNOMODULATORY THERAPIES | CELGENE CORP (US) | 2017-08-24 | — | — | US | disclosed |
| US-9732064-B2 | 5-substituted quinazolinone derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| US-9587281-B2 | Cereblon isoforms and their use as biomarkers for therapeutic treatment | CELGENE CORPORATION (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160356778-A1 | METHODS FOR DETERMINING DRUG EFFICACY FOR TREATMENT OF CANCER USING RATIOS OF CEREBLON ASSOCIATED PROTEINS | CELGENE CORPORATION | 2016-12-08 | — | — | US | disclosed |
| US-9474757-B2 | Methods for treating cancer using TOR kinase inhibitor combination therapy | SIGNAL PHARMACEUTICALS, LLC (US) | 2016-10-25 | — | — | US | disclosed |
| US-9119854-B2 | Methods for treating cancer using combination therapy | CELGENE CORPORATION (US) | 2015-09-01 | — | — | US | disclosed |
| US-20150152511-A1 | CEREBLON ISOFORMS AND THEIR USE AS BIOMARKERS FOR THERAPEUTIC TREATMENT | CELGENE CORPORATION | 2015-06-04 | — | — | US | disclosed |
| US-20150080419-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2015-03-19 | — | — | US | disclosed |
| US-8921385-B2 | 5-substituted quinazolinone derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2014-12-30 | — | — | US | disclosed |
| US-8901110-B2 | Use of biomarkers in methods for the treatment of hepatocellular carcinoma | CELGENE CORPORATION (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140328832-A1 | METHODS FOR TREATING CANCER USING COMBINATION THERAPY | CELGENE CORPORATION (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140314753-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | SIGNAL PHARMACEUTICALS, LLC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-20130183675-A1 | BIOMARKERS FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA | CELGENE CORPORATION (US) | 2013-07-18 | — | — | US | disclosed |
| US-20110111396-A1 | BIOMARKERS FOR MONITORING THE TREATMENT BY QUINAZOLINONE COMPOUNDS | SCHAFER PETER H | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140314753-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | MTOR, CHEK2, ULK1 | DDB1 491/4885CRBN 1790/4885IKZF3 3439/4885 |
| US-20150080419-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | IL5, IL6, PGF | DDB1 4060/4885CRBN 3139/4885IKZF3 4145/4885 |
| US-20160356778-A1 | METHODS FOR DETERMINING DRUG EFFICACY FOR TREATMENT OF CANCER USING RATIOS OF CEREBLON ASSOCIATED PROTEINS | CRBN, UBQLN2, CDR2 | DDB1 121/4885CRBN 1/4885IKZF3 1840/4885 |
| US-20170242014-A1 | METHODS FOR TREATING SOLID TUMORS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO IMMUNOMODULATORY THERAPIES | TSG101, IFNG, IL2 | DDB1 461/4885CRBN 951/4885IKZF3 296/4885 |
| US-20170362660-A1 | CEREBLON ISOFORMS AND THEIR USE AS BIOMARKERS FOR THERAPEUTIC TREATMENT | CRBN, CDR2, PMP22 | DDB1 1337/4885CRBN 1/4885IKZF3 1569/4885 |
| US-20150152511-A1 | CEREBLON ISOFORMS AND THEIR USE AS BIOMARKERS FOR THERAPEUTIC TREATMENT | CRBN, CDR2, PMP22 | DDB1 1337/4885CRBN 1/4885IKZF3 1569/4885 |
| US-20170369471-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | IL5, IL6, PGF | DDB1 4060/4885CRBN 3139/4885IKZF3 4145/4885 |
| US-20140328832-A1 | METHODS FOR TREATING CANCER USING COMBINATION THERAPY | TP53, TOP2A, BRCA1 | DDB1 59/4885CRBN 475/4885IKZF3 2186/4885 |
| US-10034872-B2 | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies | CHP1, MCL1, CSGALNACT1 | DDB1 233/4885CRBN 54/4885IKZF3 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.